Tirzepatide cuts body weight by 10% and insulin needs by 22% in Type 1 diabetes with obesity
Background
Managing Type 1 diabetes (T1D) is complex, and the increasing prevalence of overweight and obesity in this population exacerbates challenges, contributing to insulin resistance, higher insulin requirements, and increased cardiovascular risk. Current T1D management primarily focuses on exogenous insulin, which can itself promote weight gain, creating a vicious cycle. There's a critical need for adjunctive therapies that can improve metabolic outcomes beyond glycemic control, specifically addressing weight management and insulin sensitivity without compromising glycemic stability. Dual GLP-1R and GIPR agonists like tirzepatide, proven effective in Type 2 diabetes (T2D), offer a promising mechanism to address these unmet needs in T1D.
Study Design
This retrospective matched cohort study included 23 adults with Type 1 diabetes and BMI ≥27 kg/m2 treated with tirzepatide, propensity score-matched to 23 control participants. Participants were identified from Royal North Shore Hospital and the Northern Sydney Endocrine Centre between 2020 and 2025, with available baseline and follow-up electronic medical record data and CGM use. The most common dose of tirzepatide was 5 mg/week (52.2% of participants). Primary outcomes assessed changes in percentage body weight, HbA1c, total daily insulin dose, and CGM-derived metrics from baseline to a mean follow-up of 28 weeks for the tirzepatide group and 31 weeks for controls.
Results
Adjunctive tirzepatide treatment was associated with significant improvements in key metabolic parameters. Compared with controls, tirzepatide led to a greater reduction in body weight, averaging -10.01% ± 4.74% versus a gain of +0.69% ± 3.77% in controls (adj-p < 0.0001). This substantial weight loss was accompanied by a clinically meaningful decrease in insulin requirements. Total daily insulin dose was reduced by -21.82 ± 16.30 U/day in the tirzepatide group, while controls saw an increase of +5.62 ± 11.63 U/day (adj-p = 0.002).
Key Findings
- Tirzepatide reduced body weight by -10.01% compared to +0.69% in controls (adj-p < 0.0001).
- Total daily insulin dose decreased by -21.82 U/day with tirzepatide vs. +5.62 U/day increase in controls (adj-p = 0.002).
- Tirzepatide was associated with reductions in
glucose management indicatorandglucose SD. - The most common effective dose of tirzepatide was 5 mg/week.
- No significant differences were observed in other
CGMmetrics, blood pressure, lipid, hepatic, or renal outcomes.
Why It Matters
This study provides compelling real-world evidence that adjunctive tirzepatide can significantly improve weight management and reduce insulin burden in Type 1 diabetes patients with overweight or obesity. For individuals with T1D, managing weight while maintaining glycemic control is a major challenge, often complicated by insulin-induced weight gain. The observed 10% weight loss and 22% reduction in insulin dose could profoundly impact quality of life, reduce the risk of insulin resistance, and potentially mitigate long-term cardiovascular complications. While larger prospective studies are needed, these findings suggest that tirzepatide could become a valuable tool in the T1D therapeutic arsenal, offering a new pathway for better metabolic health beyond traditional insulin regimens. The 5 mg/week dose was most common, providing an initial protocol reference for further research.
tirzepatide
type-1-diabetes
obesity
weight-loss
insulin-reduction
glp-1-agonist